The USA's Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative ...

Experts see tolebrutinib as part of a broader shift toward treatments that target the neurodegeneration in MS, not just its ...

Fenebrutinib significantly reduced new lesions with active inflammation in people with relapsing MS in a Phase 2 trial.

A major scientific breakthrough has identified the Epstein-Barr virus (EBV) as the leading cause of multiple sclerosis (MS), a chronic inflammatory disease that affects nearly 3 million people ...

Sanofi's SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration Designation earned for a one-time intravitreal gene therapy designed to inhibit ...

The US Food and Drug Administration(FDA) has granted Fast Track designation to two non-mRNA combination vaccine candidates put forward by Sanofi.

American depositary receipts of Adagene rose 15% in premarket trading following an investment from Sanofi. ADRs were trading around $2.24. The stock is down 2% on the year. Sanofi agreed to invest ...

Thermo Fisher Scientific is expanding its partnership with Sanofi to enable additional U.S. drug-product manufacturing. Under the expanded partnership, Thermo Fisher will acquire Sanofi's sterile ...

(RTTNews) - Sanofi S.A. (SNYNF,SNY) said that the U.S. Food and Drug Administration has granted fast track designation to SAR446597, a one-time intravitreal gene therapy for the treatment of ...

Adagene Announces Upto $25 Mln Investment From Sanofi, Stock Up In Pre-Market July 01, 2025 — 08:11 am EDT Written by RTTNews.com for RTTNews -> ...